These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31951748)

  • 21. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
    Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
    Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
    J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis.
    Lin L; Liu X; Wang D; Zheng C
    Medicine (Baltimore); 2015 Mar; 94(10):e556. PubMed ID: 25761174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vedolizumab: first global approval.
    Poole RM
    Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.
    Ma C; Kotze PG; Almutairdi A; Jairath V; Panaccione R
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2374-2376.e2. PubMed ID: 30528845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
    Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
    Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
    AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
    [No Abstract]   [Full Text] [Related]  

  • 32. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
    D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.